Evotec SE Stock Deutsche Boerse AG
Stocks
EVT
DE0005664809
Biotechnology & Medical Research
OTC Markets Traded|
Market Closed -
Deutsche Boerse AG
15:41:48 2026-09-11 EDT
|
5-day change | 1st Jan Change | ||
| 2.974 EUR | -0.87% |
|
-7.12% | -45.53% |
| 09-09 | Evotec Initiates Phase 1 Trial of Potential Smallpox, Mpox Treatment | MT |
| 09-09 | Evotec Commences Early-stage Study of Potential Orthopoxvirus Therapy | MT |
| Market Cap | 528M 612M 500M 453M 849M 58.5B 854M 5.93B 2.28B 29.76B 2.3B 2.25B 94.04B | P/E 2026 * |
-2.53x | P/E 2027 * | -6.9x |
|---|---|---|---|---|---|
| Enterprise Value | 670M 778M 635M 575M 1.08B 74.34B 1.08B 7.54B 2.9B 37.82B 2.92B 2.86B 120B | EV / Sales 2026 * |
1.12x | EV / Sales 2027 * | 0.95x |
| Free-Float |
89.91% | Yield 2026 * |
-
| Yield 2027 * | - |
| Markets | Quality | ||
|---|---|---|---|
Xetra
| EVT | Delayed | |
Tradegate
| EVT | Real-time | |
|
CBOE
| EVTd | Real-time | |
|
Boerse Muenchen
| EVT | Real-time | |
|
Börse Stuttgart
| EVT | Delayed | |
|
Borsa Italiana
| 1EVT | End-of-day quote | |
|
Deutsche Boerse AG
| EVT | Delayed | |
|
Wiener Boerse
| EVT | End-of-day quote | |
|
OTC Markets
| EVOTF | Delayed | |
|
Bulgaria S.E.
| EVT | End-of-day quote | |
|
London S.E.
| 0IRF | Delayed | |
|
CBOE
| 0IRF | Real-time | |
|
Swiss Exchange
| EVT | Delayed |
Last Transcript : Evotec SE
| 1 day | -0.87% | ||
| 1 week | -7.12% | ||
| Current month | -7.87% | ||
| 1 month | -15.99% | ||
| 3 months | -36.40% | ||
| 6 months | -27.64% | ||
| Current year | -45.53% |
| 1 week | 2.91 |  | 3.19 |
| 1 month | 2.91 | | 3.47 |
| Current year | 2.91 | | 6.66 |
| 1 year | 2.91 | | 7.49 |
| 3 years | 2.91 | | 23.25 |
| 5 years | 2.91 | | 45.7 |
| 10 years | 2.91 | | 45.7 |
| Manager | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 55 | 2024-06-30 | |
| Director of Finance/CFO | - | 2026-04-30 | |
Ingrid Müller
COO | Chief Operating Officer | - | 2026-04-30 |
| Director | Title | Age | Since |
|---|---|---|---|
Roland Sackers
BRD | Director/Board Member | 58 | 2019-06-18 |
| Director/Board Member | 64 | 2021-05-31 | |
Duncan McHale
BRD | Director/Board Member | 59 | 2024-06-09 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -0.87% | -7.12% | - | - | 612M | |
| -0.71% | -6.35% | -2.99% | +9.37% | 45.48B | |
| +0.21% | -2.98% | +337.74% | +520.30% | 43.68B | |
| +1.74% | -2.24% | +39.82% | +20.85% | 43.09B | |
| +1.38% | -3.28% | +6.84% | +73.19% | 39.4B | |
| -1.44% | -5.26% | +8.97% | +39.76% | 31.91B | |
| +0.87% | -2.60% | - | - | 17.31B | |
| +0.75% | -0.64% | +19.75% | +108.58% | 16.4B | |
| -0.31% | -2.78% | +10.78% | +30.20% | 14.24B | |
| +1.93% | -3.55% | +82.00% | +36.66% | 13.28B | |
| Average | +0.35% | -3.20% | +62.86% | +104.87% | 29.42B | |
| Weighted average by Cap. | +0.41% | -3.50% | +74.57% | +124.86% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 601M 697M 569M 516M 967M 66.63B 972M 6.76B 2.6B 33.9B 2.62B 2.56B 107B | 724M 840M 686M 621M 1.17B 80.29B 1.17B 8.14B 3.13B 40.85B 3.16B 3.09B 129B |
| Net income | -202M -234M -191M -173M -325M -22.4B -327M -2.27B -874M -11.39B -880M -861M -36.01B | -48.25M -56M -45.69M -41.41M -77.69M -5.35B -78.08M -543M -209M -2.72B -210M -206M -8.6B |
| Net Debt | 143M 166M 135M 123M 230M 15.84B 231M 1.61B 618M 8.06B 623M 609M 25.46B | 162M 188M 154M 139M 261M 17.98B 262M 1.82B 701M 9.15B 707M 691M 28.91B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26-09-11 | €2.974 | -0.87% | 5,300 |
| 26-09-10 | €3.000 | -3.85% | 3,500 |
| 26-09-09 | €3.120 | -1.70% | 2,000 |
| 26-09-08 | €3.174 | -0.13% | 4,190 |
| 26-09-07 | €3.178 | -0.75% | 3,421 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- EVT Stock
- EVT Stock
Select your edition
All financial news and data tailored to specific country editions
